Meeting
2021 Genitourinary Cancers Symposium
Early surrogate measures for ablative therapies for intermediate-risk prostate cancer patients.
Authors
Rachel Glicksman
Department of Radiation Oncology, University of Toronto, Toronto, ON, Canada
Rachel Glicksman , Amar Upadhyaya Kishan , Alan W. Katz , Constantine Anastasios Mantz , Sean P. Collins , Donald B. Fuller , Liying Zhang , Andrew Loblaw
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session: Prostate Cancer - Localized Disease
Track
Prostate Cancer - Localized
Sub Track
Therapeutics
Citation
J Clin Oncol 39, 2021 (suppl 6; abstr 241)
DOI
10.1200/JCO.2021.39.6_suppl.241
Abstract #
241
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Genitourinary Cancers Symposium
Biochemical disease control outcomes of stereotactic body radiation therapy (SBRT) or moderate hypo-fractionation (HFRT) for low- and intermediate-risk prostate cancer (PrCa): Retrospective analysis of 12 years of experience at two Canadian cancer centers.
First Author: Hsin-pei (Spencer) Hu
Poster
2024 ASCO Genitourinary Cancers Symposium
Time to next systemic therapy after stereotactic body radiation therapy for oligoprogressive metastatic castrate-resistant prostate cancer.
First Author: Corbin J. Eule
Poster
2023 ASCO Annual Meeting
Predicting absolute benefit in risk of metastasis of androgen deprivation therapy added to radiation therapy in patients with newly diagnosed prostate cancer using Prolaris.
First Author: Jonathan David Tward
Poster
2023 ASCO Genitourinary Cancers Symposium
NRG-GU011: A phase II double-blinded, placebo-controlled trial of prostate oligometastatic radiotherapy with or without androgen deprivation therapy in oligometastatic prostate cancer (NRG PROMETHEAN).
First Author: Bridget F. Koontz